Glenview Trust’s iShares Biotechnology ETF IBB Stock Holding History

Glenview Trust’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-3,490	Closed	-$383K	–	329
2018 Q2	$383K	Buy	+3,490	New	+$373K	0.03%	234

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Glenview Trust's IBB Position: Q3 2018 in Review

Glenview Trust sold out of iShares Biotechnology ETF (IBB) in Q3 2018, closing a stake of 3,490 shares — an estimated $383K sold.

Glenview Trust first reported a position in IBB in Q2 2018 and held it in 1 quarter. The position peaked at $383K in Q2 2018. 631 funds tracked by Wall St. Rank hold IBB as of Q3 2018.

Glenview Trust reported no remaining iShares Biotechnology ETF position as of Q3 2018 after selling out during the quarter.
Glenview Trust sold 3,490 iShares Biotechnology ETF shares in Q3 2018, an estimated $383K.
Glenview Trust first reported a position in iShares Biotechnology ETF in Q2 2018 and held it in 1 quarter.
Glenview Trust's iShares Biotechnology ETF position peaked at $383K in Q2 2018.
631 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2018.

Based on Glenview Trust's 13F filing for Q3 2018, filed 14 Nov 2018.